APYX Apyx Medical Dashboard

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Company profile

Ticker

APYX

Exchange

NASDAQ

Website

apyxmedical.com/

CEO

Charles Goodwin

Incorporated

Delaware

Location

Florida

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Boston Scientific • Baxter International • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...

Former names

AN CON GENETICS INC, BOVIE MEDICAL CORP, BOVIE MEDICAL Corp

SEC CIK

0000719135

Corporate docs

Articles of Incorporation & Bylaws

IRS number

112644611

APYX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Apyx Medical Corporation Announces FDA 510(k) Submission For Use Of Renuvion In Dermal Resurfacing Procedures

1 Jun 21

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery

ROCE Insights For Apyx Medical

26 May 21

In Q1, Apyx Medical (NASDAQ:APYX) posted sales of $8.64 million. Earnings were up 151.59%, but Apyx Medical still reported an overall loss of $4.84 million. In Q4, Apyx Medical brought in $11.46 million in sales but lost $1.92 million in earnings.

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron

12 May 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)

Apyx Medical Q1 EPS $(0.14), Inline, Sales $8.60M Up From $5.00M YoY

12 May 21

Earnings Scheduled For May 12, 2021

12 May 21

Press releases

Pro users get this 30m faster

Apyx Medical Corporation to Participate in the JMP Securities Life Sciences Conference

3 Jun 21

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and

Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of Renuvion® in Dermal Resurfacing Procedures

1 Jun 21

Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook

12 May 21

Advanced Energy Sales increased 92% year-over-year in Q1 Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold

Apyx Medical Corp. to Host Earnings Call

12 May 21

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

12 Apr 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 21

17 Jun 21

31 Dec 21

Financial summary

Financial statements Chart APYX financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	39.54M	39.54M	39.54M	39.54M	39.54M	39.54M
Cash burn (monthly)	792K	986.75K	1.61M	1.46M	684K	892.58K
Cash used (since last report)	2.03M	2.53M	4.13M	3.74M	1.75M	2.29M
Cash remaining	37.51M	37.01M	35.41M	35.8M	37.79M	37.25M
Runway (months of cash)	47.4	37.5	22.0	24.5	55.2	41.7

Beta Read what these cash burn values mean

Recent insider trades

APYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 Mar 21	Waldman Lawrence	Common Stock	Option exercise	Aquire M	No	No	2.81	5,563	15.63K	5,563
8 Mar 21	Waldman Lawrence	Stock Option (Option to Buy) Common Stock		Dispose X	No	No	2.81	7,500	21.08K	0
5 Mar 21	Michael Geraghty	Common Stock	Option exercise	Aquire M	No	No	2.81	7,500	21.08K	7,500
5 Mar 21	Michael Geraghty	Stock Option (Option to Buy) Common Stock		Dispose X	No	No	2.81	7,500	21.08K	0
29 Jan 21	Tara Semb	Stock Option (Option to Buy) Common Stock	Grant	Aquire A	No	No	9.29	48,000	445.92K	48,000
29 Jan 21	Goodwin Charles D. II	Common Stock Common Stock	Grant	Aquire A	No	No	9.29	121,500	1.13M	121,500
29 Jan 21	Todd Hornsby	Stock Option (Option to Buy) Common Stock	Grant	Aquire A	No	No	9.29	50,000	464.5K	50,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

APYX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Medtronic • Conmed • Medtronic • Inmode

Management Discussion

Total revenue increased by 72.9%, or approximately $3.6 million, for the three months ended March 31, 2021 when compared with the three months ended March 31, 2020. Advanced Energy segment sales increased 92.2%, or approximately $3.7 million, for the three months ended March 31, 2021 when compared with the three months ended March 31, 2020. In the first quarter of 2021, we saw increased global demand for both our handpieces and generators. While demand for generators in certain geographic regions continues to be affected by the impacts of the COVID-19 pandemic, we experienced strong sales volumes overall during the first quarter.
International sales represented approximately 35.6% and 27.6% of total revenues for the three months ended March 31, 2021 and 2020, respectively. Management estimates our products have been sold in more than 55 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.
Gross profit for the three months ended March 31, 2021, increased 96.4% to $5.9 million, compared to $3.0 million for the same period in the prior year. Gross margin for the three months ended March 31, 2021, was 67.8%, compared to 59.7% for the same period in 2020. The increase in profit margins for the three months ended March 31, 2021 from the prior year period is primarily attributable to sales mix between our two segments, with our Advanced Energy segment comprising a higher percentage of total sales, as well as product mix within our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives and the introduction of newer product models.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accurately, assessment, automated, cautiously, challenging, chapter, check, complying, comprised, comprising, confidence, consumer, Delaware, ease, electronically, emerge, emerging, Employer, enterprise, Equity, ERP, extended, fee, filer, FL, flow, Identification, incorporated, incorporation, Interactive, introduction, jurisdiction, mark, Mine, modified, optimistic, par, permanently, pose, preceding, Qualitative, Quantitative, recall, Regulation, rely, replaced, resource, Road, section, Senior, shell, shorter, sluggish, Strike, Title, toe, type, Ulmerton, uneven, Unregistered, Washington, wholly

Removed: accrue, accuracy, acquired, actively, adherence, adjusted, Administration, alleging, amendment, American, application, appointed, approved, approving, assigning, assist, audited, authorization, back, BDO, behalf, Bulgarian, burdensome, cancel, chain, charge, choose, Codification, collect, collection, committed, Committee, comparing, complaint, complex, complexity, compliance, compute, consistent, context, Controller, counsel, court, created, curtailed, curtailment, decline, deeper, defer, deferral, deficiency, degree, delay, delayed, denominated, dermal, design, designing, detect, detected, deteriorate, developing, disposable, disruption, District, document, documentation, domestically, Drug, economy, engineer, enhanced, enhancing, epidemic, estimation, European, evidence, executing, exempt, expeditiously, expose, extension, external, facility, failure, fairly, FDA, February, finance, firm, Food, footnote, forfeiture, framework, fully, furlough, geographical, goodwill, Goodwin, granting, greater, immaterial, implied, inadequate, ineffective, Integrated, internationally, January, July, knowledge, lack, Latin, lattice, lead, lifted, limited, LLP, member, Middle, mitigate, motion, multiple, network, North, noted, Notification, outlined, oversight, pay, payroll, perform, performed, plaintiff, planned, portion, positive, Premarket, present, President, prevented, processing, procure, production, program, purpose, putative, qualified, receive, recently, recruit, redirect, reduction, refund, released, reliability, reliable, remediate, remediated, remediating, remit, resolving, responsible, resulted, resurfacing, resurgence, retrospective, revising, sale, scale, scope, selection, September, set, shut, Simplifying, slowdown, Sponsoring, submission, Subsequent, temporarily, test, thereunder, train, Treadway, trinomial, unable, undergo, underlying, unit, USA, validating, variability, variance, vendor, verifying, volume, voluntarily

From filing 10-Q 2021 Q1